Lynn D. Hudson, PhD

Dr. Lynn Hudson serves as the Chief Science Officer for the Critical Path Institute and Executive Director of both the Multiple Sclerosis Outcome Assessments Consortium and the International Neonatal Consortium. She also co-chairs the Scientific Advisory Committee of CFAST. She received a Bachelor of Science degree in Biochemistry at the University of Wisconsin, a doctorate in Genetics and Cell Biology at the University of Minnesota, and post-doctoral training at Harvard Medical School and Brown University. Combining science and policy, Dr. Hudson conducted research in the National Institute of Neurological Disorders and Stroke (NINDS) intramural program and directed the Office of Science Policy Analysis at the National Institutes of Health (NIH) from 2006 to 2011. As a major source for policy analysis within the NIH’s Office of the Director, her office covered a wide spectrum of sensitive and emerging issues and oversaw a number of programs, including the AAAS/NIH Science Policy Fellowship program, NIH’s contract with the National Academy of Sciences, and the Public-Private Partnership Program. Her policy team’s awards cite contributions to NIH’s Congressional Justification, Biennial Report, implementation of the NIH Reform Act, Stem Cell Guidelines, and Comparative Effectiveness Research.

As Chief of the Section of Developmental Genetics, Dr. Hudson received the NIH Merit Award for her discovery of the causative mutations in the neurologic disorder Pelizaeus-Merzbacher disease (PMD), and an NINDS Award for educational outreach efforts. Dr. Hudson’s research focused on defining the network of genes involved in the development of glial cells, with the goal of designing strategies to overcome glial dysfunction in inherited or acquired neurological diseases. She served as an elected officer for the American Society for Neurochemistry, an officer on the scientific advisory board of the PMD Foundation, and as an advisor for a number of granting agencies and disease foundations, including the National Multiple Sclerosis Society. Presently, Dr. Hudson serves on the National Academies of Science (NAS) Forum on Drug Discovery, Development, and Translation. She has a Research Professor appointment in the College of Medicine at the University of Arizona. She is also a board member of BIOSA, the BioIndustry Organization of Southern Arizona, and was honored by AZBIO as the 2015 Arizona Bioscience Leader of the Year.